The effect of octreotide treatment on somatic and psychological symptoms of acromegaly

Neuroendocrinology Letters

Volumn 31, Issue 2, 2010, Pages 265-269

  Ruchala, Marek ^a   Stangierska, Izabela ^a   Gurgul, Edyta ^a   Stangierski, Adam ^a   Fajfer, Jolanta ^a   Sowinski, Jerzy ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Acromegaly; Life satisfaction; Octreotide; Quality of life; Somatostatin analog

Indexed keywords

OCTREOTIDE; GROWTH HORMONE; SOMATOSTATIN;

ACROMEGALY; ADULT; AMENORRHEA; ANALGESIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; COGNITION; DEFENSE MECHANISM; DEPRESSION; EMOTION; FEMALE; HEADACHE; HUMAN; HUMAN RELATION; HYPERHIDROSIS; IMPOTENCE; INSOMNIA; IRRITABILITY; LIFE SATISFACTION; MALE; MEMORY DISORDER; MENTAL INSTABILITY; PSYCHOLOGIC TEST; PSYCHOMOTOR ACTIVITY; QUALITY OF LIFE; SELF CONCEPT; SEX ROLE; SOCIAL ISOLATION; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; MOTOR ACTIVITY; PSYCHOLOGY; SEX DIFFERENCE; TREATMENT OUTCOME;

ACROMEGALY; ADULT; ARTHRALGIA; COGNITION; FEMALE; FOLLOW-UP STUDIES; GROWTH HORMONE; HEADACHE; HUMANS; INTERPERSONAL RELATIONS; MALE; MIDDLE AGED; MOTOR ACTIVITY; OCTREOTIDE; QUALITY OF LIFE; SEX FACTORS; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 77952327913     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bem SL. (1981). Gender schema theory. A cognitive account of sex typing Psychological Review. 88(4): 354-364.
2. Beutler, LE, Engle D, Oro'-Beutler ME, Daldrup, R, Meredith K. (1986). Inability to express intense affect: A common link between depression and pain? Journal of Consulting Clinical Psychology. 54: 752-759.
3. Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JWA et al. (2004). Decreased Quality of Life in Patients with Acromegaly Despite Long-Term Cure of Growth Hormone Excess. J Clin Endocrinol Metab. 89(11): 5369-5376.
4. Chan JM, Stampfer MJ, Giovanucci E, Gann PH, Ma J, Wilkinson P et al. (1998). Plasma insulin-like growth factor I and prostate cancer risk: a prospective study. Science. 279: 563-566;
5. Chanson P, Salenave S. (2008) Acromegaly. Review. Orphanet J Rare Dis. 3: 1-17.
6. Clayton RN, 2003. Cardiovascular function in acromegaly. Endocr Rev. 24: 272-277
7. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, et al. (2000). Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 85: 193-199
8. Colao A, Ferone D, Marzullo P et al. (2001). Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 86: 2779-2786. (Pubitemid 32545739)
9. Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME et al. (1990). Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res. 50: 48-53. (Pubitemid 20029992)
10. Freda PU. (2002). Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 87: 3013-3018
11. Freda PU. (2003). How effective are current therapies for acromegaly? Growth hormone & IGF research 13: 144-151.
12. Gapinska B, Tartas M, Walkiewicz M, Majkowicz M,. (2008). Self-efficacy and anxiety and depression in patients with colostomy. Wspolczesna Onkologia 12(2): 84-89. (Pubitemid 351780851)
13. Garsen B. (2007). Repression: Finding Our Way in the Maze of Concepts. J Behav Med. 30(6): 471-481. (Pubitemid 350171278)
14. Gola M, Doga M, Bonadonna S, Mazziotti G, Vescovi PP, Giustina A. (2006). Neuroendocrine tumors secreting growth hormone-releasing hormone: pathophysiological and clinical aspects. Pituitary. 9: 221-229
15. Grunstein RR, Ho KK, Sullivan CE. (1994). Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med. 121: 478-483
16. Jenkins PJ, Besser M. (2001). Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab. 86: 2935-2941
17. Jensen MR. (1987). Psychobiological factors predicting the course of breast cancer. Journal Personality 55: 317-342.
18. John OP, Gross JJ. (2004). Healthy and unhealthy emotion regulation: Personality processes, individual differences, and life span development. Journal of Personality. 72: 1301-1333
19. Juczynski Z. (2001). Narzȩdzia pomiaru w promocji i psychologii zdrowia [Tools for Health Assessment in Health Promotion and Psychology] (in Polish), Warszawa, Pracownia Testow Psychologicznych Polskiego Towarzystwa Psychologicznego.
20. Kauppinen-Mäkelin R, Sane T, Sintonen H, Markkanen H, Välimäki MJ, Löyttyniemi E et al. (2006). Quality of Life in Treated Patients with Acromegaly. J Clin Endocrinol Metab. 91(10): 3891-3896.
21. Lancranjan I, Atkinson AB. (1999). Results of a European multi-centre study with Sandostatin LAR in acromegaly patients. Pituitary 1: 105-114.
22. Liote F, Orcel P. (2000). Osteoarticular disorders of endocrine origin. Baillieres Best Pract Res Clin Rheumatol. 14: 251-276
23. Matyja V, Kos-Kudla B, Foltyn W, Strzelczyk J, Latos W, Marek B et al. (2006). Detection of colorectal lesions by using autofluorescence colonoscopy in acromegalics and their relation to serum growth hormone and insulin-like growth factor-1 levels. Neuroendocrinol Lett. 27(5): 639-643.
24. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M et al. (1998). Increased incidence of neoplasia in patients with pituitary adenomas. Clin Endocrinol. 49 (4): 441-445.
25. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM and Rainer PJ. (2005). Quality of Life (QOL) in Patients with Acromegaly Is Severely Impaired: Use of a Novel Measure of QOL: Acromegaly Quality of Life Questionnaire. J Clin Endocrinol Metab 90(6): 3337-3341. (Pubitemid 41014295)
26. Ruchala M, Skiba A, Gurgul E, Uruski P, Wasko R, Sowinski J. (2009). The occurrence of thyroid focal lesions and a need for fine needle aspiration biopsy in patients with acromegaly due to an increased risk of thyroid cancer. Neuroendocrinol Lett. 30(3): 382-386.
27. Scacchi M, Cavagnini F. (2006). Acromegaly. Pituitary. 9: 297-303.
28. Sze L, Schmid C, Bloch KE et al. (2007) Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol. 156: 321-329 (Pubitemid 46554500)
29. Turner HE, Vadivale A, Keenan J, Wass JA. (1999). A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf). 551: 275-280. (Pubitemid 29439045)
30. Weihs KL, Enright TM, Simmens SJ, Reiss D. (2000). Negative affectivity, restriction of emotions, and site of metastases predict mortality in recurrent breast cancer. Journal of Psychosomatic Research. 49: 59-68.
31. Foltyn W, Kos-Kudla B, Strzelczyk J, Matyja V, Karpe J, Rudnik A et al. (2008). Is there any relation between hyperinsulinemia,insulin resistance and colorectal lesions in patients with acromegaly? Neuroendocrinol Lett. 29(1): 107-112
32. Lancrajan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P et al. (1996). Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism. 45: 67-71.
33. Pawlikowski MG. Melen-Mucha. (2003). Perspectives of new potential therapeutic applications of somatostatin analogs. Neuroendocrinol Lett 24: 21-27